Newborn Screening Market Size, Share & Trends Report

Newborn Screening Market Size, Share & Trends Analysis Report By Technology (Tandem Mass Spectrometry, Pulse Oximetry), By Test Type, By Product (Instruments, Reagents), By Region, And Segment Forecasts, 2023 - 2030

Report ID: 978-1-68038-490-1
Number of Pages: 180
Format: Electronic (PDF)

Historical Range: 2018 - 2021
Industry: Healthcare

Market Segmentation

Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
- Tandem Mass Spectrometry
- Pulse Oximetry
- Enzyme-based Assay
- DNA Assays
- Electrophoresis
- Others
Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
- Dry Blood Spot Test
- CCHD
- Hearing Screen
Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
- Instruments
- Reagents
Newborn Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Instruments
    - Reagents & Assay Kits
  - North America Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
    - Tandem Mass Spectrometry
    - Pulse Oximetry
    - Enzyme Based Assays
    - DNA Assays
    - Electrophoresis
    - Others
  - North America Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Dry Blood Spot Test
    - Critical Congenital Heart Disease (CCHD)
    - Hearing Screen
  - U.S.
    - U.S. Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - U.S. Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - U.S. Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Canada
    - Canada Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Canada Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Canada Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
- Europe
  - Europe Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Instruments
    - Reagents & Assay Kits
  - Europe Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
    - Tandem Mass Spectrometry
    - Pulse Oximetry
    - Enzyme Based Assays
    - DNA Assays
    - Electrophoresis
    - Others
  - Europe Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Dry Blood Spot Test
    - Critical Congenital Heart Disease (CCHD)
    - Hearing Screen
  - U.K.
    - U.K. Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - U.K. Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - U.K. Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Germany
    - Germany Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Germany Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Germany Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - France
    - France Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - France Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - France Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Italy
    - Italy Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Italy Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Italy Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Spain
    - Spain Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Spain Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Spain Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Sweden
    - Sweden Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Sweden Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Sweden Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Denmark
    - Denmark Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Denmark Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Denmark Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Norway
    - Norway Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Norway Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Norway Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
- Asia Pacific
  - Asia Pacific Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Instruments
    - Reagents & Assay Kits
  - Asia Pacific Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
    - Tandem Mass Spectrometry
    - Pulse Oximetry
    - Enzyme Based Assays
    - DNA Assays
    - Electrophoresis
    - Others
  - Asia Pacific Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Dry Blood Spot Test
    - Critical Congenital Heart Disease (CCHD)
    - Hearing Screen
  - Japan
    - Japan Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Japan Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Japan Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - China
    - China Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - China Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - China Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - India
    - India Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - India Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - India Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Australia
    - Australia Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Australia Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Australia Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - South Korea
    - South Korea Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - South Korea Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - South Korea Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Thailand
    - Thailand Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Thailand Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Thailand Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
- Latin America
  - Latin America Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Instruments
    - Reagents & Assay Kits
  - Latin America Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
    - Tandem Mass Spectrometry
    - Pulse Oximetry
    - Enzyme Based Assays
    - DNA Assays
    - Electrophoresis
    - Others
  - Latin America Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Dry Blood Spot Test
    - Critical Congenital Heart Disease (CCHD)
    - Hearing Screen
  - Brazil
    - Brazil Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Brazil Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Brazil Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Mexico
    - Mexico Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Mexico Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Mexico Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Argentina
    - Argentina Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Argentina Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Argentina Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
- MEA
  - MEA Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
    - - Instruments
      - Reagents & Assay Kits
  - MEA Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
    - - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
  - MEA Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
    - - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - South Africa
    - South Africa Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - South Africa Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - South Africa Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Saudi Arabia
    - Saudi Arabia Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Saudi Arabia Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Saudi Arabia Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - UAE
    - UAE Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - UAE Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - UAE Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen
  - Kuwait
    - Kuwait Newborn Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Instruments
      - Reagents & Assay Kits
    - Kuwait Newborn Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
      - Tandem Mass Spectrometry
      - Pulse Oximetry
      - Enzyme Based Assays
      - DNA Assays
      - Electrophoresis
      - Others
    - Kuwait Newborn Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Dry Blood Spot Test
      - Critical Congenital Heart Disease (CCHD)
      - Hearing Screen

Newborn Screening Market Dynamics

Driver: Growing neonatal population base

The base of newborns worldwide is growing. Over 88 billion births were recorded in 2015, or almost 250 births every minute, according to the World Population Meter. Of these, due to inadequate screening and expert treatment, almost 2.8 million newborns pass away in the first month of life. Organizations like the WHO, CDC, Healthy Newborn Network, etc. are working to inform parents about potential problems and associated diagnostic processes to stop this number from increasing. In addition, organizations in North America have mandated that all newborns born in hospitals under the private sector undergo screening. Programs are concentrated in Asia Pacific since the region is seeing an increase in infant birth and death. In addition to paying for the first examination, the Japanese Ministry of Health suggested using tandem mass spectroscopy to check for more than 29 serious illnesses.

Government programs and legislation

The WHO recommends the newborn screening program as a way to protect children's health worldwide. The U.S. Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC), the International Society for Neonatal Screening, the Japan Society of Obstetrics and Gynecology (JSOG), Pediatric Epidemiology and Community Health, UK (PEACH), the National Newborn Screening and Genetics Resource Center, and advocacy organizations such as the March of Dimes have all taken several policies and initiatives under this program. Most states have newborn screening legislation that explicitly outlines the program's financing, the conditions under which it must be performed, and the exceptions to the rule. President George W. Bush signed the Newborn Screening Saves Lives Act 2007 into law to safeguard newborns and create grant programs. According to the statute, every newborn must be evaluated for a minimum of 29 diseases, which include severe combination immunodeficiencies and congenital cardiac heart disease (CCHD). The Baby's First Test educational database was developed as a result of the statute.

Restraint: Rise in abortion rate due to congenital disorders

Prenatal diagnostics have advanced to the point that fetuses are showing signs of congenital abnormalities, which encourages many women to terminate their pregnancies. According to a report by the Japan Society of Obstetrics and Gynecology (JSOG), these abortions are performed without adequate knowledge of the problems, such as the developmental stage, which causes the abortion rate to rise quickly without any justification. They have thus released recommendations on the subject to stop these abortions. The JSOG states that early therapy and screening during childbirth can prevent congenital diseases without causing the fetus to die. The guidelines are intended to help medical practitioners advise parents appropriately and consider all of their choices before performing an abortion.

What Does This Report Include?

This section will provide insights into the contents included in this newborn screening market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Newborn screening market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Newborn screening market quantitative analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.